Compare peptides
Compare two to four peptides side by side. Counts are exact.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog GHRP-2 | Synthetic analog Hexarelin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 632 | 1,112 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 19 (8 in people) | 21 (13 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | None registered | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | GHRP-2 | Hexarelin |
|---|---|---|
| Growth hormone and IGF-1Musculoskeletal | 30817310431 | 369 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 22 Oct 2026).
| Stress hormonesEndocrine and hormones | 30291 | 87843 |
|---|
| Pituitary hormonesEndocrine and hormones | 21165 | 6464 |
|---|
| Heart functionCardiovascular | 1459 | 151199141 |
|---|
| Receptor activity and mechanismRespiratory | 6411152 | 105123801 |
|---|
| PharmacokineticsPharmacology | 16952 | 5052916 |
|---|
| Hormone levelsEndocrine and hormones | 7331 | 23176 |
|---|
| Appetite and food intakeMetabolic and weight | 321022 | 15114 |
|---|
| Inflammation markersRespiratory | 3511717 | 222173 |
|---|
| Bone and jointMusculoskeletal | 514 | 286193 |
|---|
| Thyroid functionEndocrine and hormones | 972 | 44 |
|---|
| Adverse eventsWhole body | 15672 | 22 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
GHRP-2 differs from Ghrelin (human), ghrelin-28 at 5 positions and carries 1 added group.
What is different
Hexarelin differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | GHRP-2 | Hexarelin |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in mu/l | 109.7 mU/l Peak GH at 30 min · GHRP-2 Dose studied: 1 microgram/kg BWn = 81995 | 6.8 mU/l Peak GH · hexarelin 0.5 microgram/kg during SS50 Dose studied: 0.5 microgram/kgn = 121997 |
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
No comparable result 28 randomized-trial results measure it in another way or another unit. |
| Hormone levelsEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | 35% Cortisol increase · GHRP-2 Dose studied: 1 microgram/kgn not reported1996 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
|---|
| Pituitary hormonesEndocrine and hormonesCompared as: difference from placebo, in % | 21% Mean PRL increase Dose studied: 1 microgram/kg bolus, then 1 microgram/kg/h21 hoursn not reported1997 | No comparable result 13 randomized-trial results measure it in another way or another unit. |
|---|
| LipidsMetabolic and weightCompared as: value in the arm that got the peptide, in % | 60% Plasma FFA rise · after GHRP-2 n = 92000 | No randomized trial result 15 results from other study designs. |
|---|
| Blood pressureCardiovascularCompared as: value in the arm that got the peptide, in mm hg | No randomized trial result 1 result from other study designs. | 92.8 mm Hg MBP n = 71999 |
|---|
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in % | No randomized trial result 14 results from other study designs. | 70.7% LVEF n = 71999 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.